Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 4 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 7Genitourinary 6Sarcoma 4CNS 3Breast 3Plasma cell 2Dermatologic 2Thoracic 1Gynecologic 1

Conditions

Hemangioma, Cavernous, Central Nervous System 2Neuroblastoma 1

Interventions

Temozolomide 258Radiotherapy 147Bevacizumab 142Etoposide 68Cyclophosphamide 68Carboplatin 66Magnetic Resonance Spectroscopy 58Irinotecan 53Cisplatin 52Vincristine 45Filgrastim 43pembrolizumab 40Radiosurgery 36Nivolumab 36Radiation 34Topotecan 31Doxorubicin 30Specimen Handling 29sargramostim 28Lomustine 27Erlotinib Hydrochloride 27Peripheral Blood Stem Cell Transplantation 25Carmustine 25Thiotepa 24Everolimus 23Chemotherapy, Adjuvant 23Surgical Procedures, Operative 22Isotretinoin 22Ipilimumab 22Melphalan 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Propranolol × CNS × Clear all
NCT02641314 2024-05-10

METRO-NB2012

University of Cologne

Phase 2 Completed
18 enrolled
CNS

Neuroblastoma

NCT03474614 2024-04-19

Effect of Oral Propranolol on mRNA Expresssion in Symptomatic Cavernous Malformation

St. Joseph's Hospital and Medical Center, Phoenix

Phase 2 Terminated
4 enrolled
CNS

Hemangioma, Cavernous, Central Nervous System

NCT03589014 2022-02-25

Treat_CCM

Mario Negri Institute for Pharmacological Research

Phase 2 Completed
71 enrolled
CNS

Hemangioma, Cavernous, Central Nervous System

Data powered by HemOnc (CC BY 4.0) Colophon âš¡